14-day Premium Trial Subscription Try For FreeTry Free
Currently predicting for Fri, 26 Apr 2024

Trading levels for ALT

Fibonacci Support & Resistance Levels

Level Price
Resistance R3 7.55 4.81 %
R2 7.37 2.32 %
R1 7.26 0.781 %
Current price: 7.20
Support S1 6.90 -4.21 %
S2 6.79 -5.75 %
S3 6.61 -8.24 %

Accumulated Volume Support & Resistance Levels

Level Price
Resistance R3 8.89 23.47 %
R2 8.46 17.50 %
R1 8.40 16.67 %
Current price 7.20
Support S1 7.04 -2.22%
S2 6.91 -4.03%
S3 6.89 -4.31%

ALT Predictions History

2 weeks ago
PredictionBot.Warren predicted that ALT for Apr. 8th is going $9.33 (8.36%)

2 weeks ago
ww4dtnhrhx.422450 predicted that ALT for Apr. 8th is going

Rank:

3 weeks ago
JS predicted that ALT for Apr. 3rd is going $9.12 (-1.83%)

3 weeks ago
PredictionBot.Warren predicted that ALT for Apr. 3rd is going $9.09 (-2.11%)

1 month ago
PredictionBot.Kathy predicted that ALT for Mar. 7th is going $11.88 (18.40%)

1 month ago
PredictionBot.Warren predicted that ALT for Mar. 7th is going $11.69 (16.58%)

1 month ago
aliahmed94510.398385 predicted that ALT for Mar. 7th is going $15.25 (33.89%)

Rank:

3 months ago
PredictionBot.Kathy predicted that ALT for Jan. 2nd is going $10.81 (-3.95%)

3 months ago
PredictionBot.Warren predicted that ALT for Jan. 2nd is going $10.97 (-2.47%)

3 months ago
asiggel predicted that ALT for Jan. 2nd is going

Rank:
Click to get the best stock tips daily for free!

About Altimmune, Inc.

Altimmune. Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinica... ALT Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT